Can-Fite BioPharma Company Description

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel.

The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis.

It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction.

In addition, It offers cannabinoids for treatment of conditions associated with elevated expression of the A3 adenosine receptors.

Further, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson.

The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001.

The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.

Can-Fite BioPharma Ltd.

Country	Israel
Founded	1994
Industry	Biotechnology
Sector	Healthcare
Employees	5
CEO	Motti Farbstein

Contact Details

Address: 26 Ben Gurion Street Ramat Gan, 5257346 Israel
Phone	972 3 924 1114
Website	canfite.com

Stock Details

Ticker Symbol	CANF
Exchange	Tel Aviv Stock Exchange
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	IL0010944739
SIC Code	2836

Key Executives

Name	Position
Dr. Pnina Fishman Ph.D.	Founder, Chief Scientific Officer and Executive Chairperson
Motti Farbstein	Chief Executive, Financial and Operating Officer
Dr. Sari Fishman Ph.D.	Vice President of Business Development
Dr. Stephen A. Harrison FACP, M.D.	Member of Clinical Advisory Board and Consulting Chief Medical Officer